Antibody Firm Affomix Readies to Launch Service Biz in the Summer; Technology for PTM Differentiation in the Works

The company aims to tackle the two major issues in the antibody field — poor quality and too few antibodies — by defining a so-called "affome," an antibody set against all proteins in the human proteome.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.